The European Medicines Agency said Thursday that its committee evaluating medical products has recommended partial approval ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

It has been years since I have considered restarting a position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) after having ...

with the switch group showing a more modest result that was still better than the no-treatment arm. According to Eisai and Biogen, that level of change on the CDR-SB can be "the difference between ...

Recent examples include Eisai and Biogen's efforts to develop an injectable ... Many of the biologic drugs that have made the switch from infusion to subcutaneous route have done so with the ...

This year, it has been joined by natalizumab (Tysabri; Elan/Biogen-Idec), a humanized antibody ... which anti-TNF-α agent to start with or to switch to are increasingly influenced by factors ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.8 ...

Not only does Nintendo continue to pump out some of the best games for its own console, but the Switch has become home to some of the best multiplatform games released over the last few years.

Apple’s ( AAPL) latest MacBook Pro line of laptops is here, and it packs a serious punch for users looking for a portable powerhouse that can handle everything from photo and video editing to gaming ...